Acura Pharmaceuticals

OverviewSuggest Edit

Acura Pharmaceuticals, a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
TypePublic
Founded1935
HQPalatine, US
Websiteacurapharm.com

Latest Updates

Employees (est.) (Dec 2018)12(-14%)
Revenue (FY, 2017)$107 K(-74%)
Share Price (Oct 2017)$0.5

Acura Pharmaceuticals Office Locations

Acura Pharmaceuticals has offices in Palatine and Culver
Palatine, US (HQ)
616 N North Ct
Culver, US
16235 State Rd 17
Show all (2)

Acura Pharmaceuticals Financials and Metrics

Acura Pharmaceuticals Revenue

Acura Pharmaceuticals's revenue was reported to be $107 k in FY, 2017
USD

Net income (Q1, 2019)

(788.0k)

EBIT (Q1, 2019)

(683.0k)

Market capitalization (8-Oct-2018)

5.8m

Cash (31-Mar-2019)

95.0k
Acura Pharmaceuticals's current market capitalization is $5.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

113.0k751.0k662.0k423.0k107.0k

Revenue growth, %

1043%(48%)

Cost of goods sold

114.0k656.0k451.0k128.0k

Gross profit

(1.0k)6.0k(28.0k)(21.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

80.0k39.0k34.0k145.0k357.0k91.0k115.0k107.0k94.0k105.0k107.0k

Cost of goods sold

78.0k38.0k42.0k108.0k324.0k98.0k132.0k102.0k99.0k108.0k128.0k

Gross profit

2.0k1.0k(8.0k)37.0k33.0k(7.0k)(17.0k)5.0k(5.0k)(3.0k)(21.0k)

Gross profit Margin, %

3%3%(24%)26%9%(8%)(15%)5%(5%)(3%)(20%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

12.3m774.0k2.5m2.7m2.2m91.0k

Inventories

629.0k471.0k276.0k309.0k

Current Assets

27.5m13.2m14.1m5.9m2.6m461.0k

PP&E

941.0k957.0k1.0m867.0k679.0k606.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

2.6m8.9m3.5m1.3m3.8m1.3m3.3m3.3m3.3m4.3m3.8m1.1m4.8m774.0k568.0k18.0k95.0k

Accounts Receivable

169.0k

Inventories

298.0k445.0k403.0k282.0k217.0k74.0k202.0k182.0k424.0k

Current Assets

20.8m23.7m18.7m16.1m15.0m11.9m16.0m11.6m7.7m5.3m6.7m4.2m5.3m1.1m916.0k455.0k316.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(13.9m)(13.2m)(5.0m)(7.4m)(5.7m)(3.8m)

Depreciation and Amortization

134.0k119.0k125.0k138.0k87.0k73.0k

Inventories

(282.0k)(254.0k)(302.0k)(59.0k)103.0k

Accounts Payable

(720.0k)(57.0k)(107.0k)(33.0k)(74.0k)602.0k
Quarterly
USDY, 2019

Financial Leverage

-0.4 x
Show all financial metrics

Acura Pharmaceuticals Online and Social Media Presence

Embed Graph

Acura Pharmaceuticals News and Updates

Acura Pharmaceuticals Announces First Quarter 2019 Financial Results

PALATINE, Ill., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced, to…

Acura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results

PALATINE, Ill., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced to…

Acura Pharmaceuticals Engages Catalent Pharma Solutions to Advance Development of LTX-03

PALATINE, Ill., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today announced that it has engaged Catalent Pharma Solutions, LLC (“Catalent”) to initiate manufacturing scale-up of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets to ultimately be used in …

Acura Pharmaceuticals Licenses LIMITx™ LTX-03

Agreement Provides For Completion of Development and CommercializationTransaction Valued at up to $21.3 Million, not including Royalties

Acura Pharmaceuticals Announces Third Quarter 2018 Financial Results

PALATINE, Ill., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018.

Acura Pharmaceuticals, Inc. Restructures Debt Obligations

PALATINE, Ill., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company focused on innovating abuse deterrent drugs, today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million loan…
Show more

Acura Pharmaceuticals Frequently Asked Questions

  • When was Acura Pharmaceuticals founded?

    Acura Pharmaceuticals was founded in 1935.

  • How many employees does Acura Pharmaceuticals have?

    Acura Pharmaceuticals has 12 employees.

  • Who are Acura Pharmaceuticals competitors?

    Competitors of Acura Pharmaceuticals include MyoKardia, Athersys and Reata Pharmaceuticals.

  • Where is Acura Pharmaceuticals headquarters?

    Acura Pharmaceuticals headquarters is located at 616 N North Ct, Palatine.

  • Where are Acura Pharmaceuticals offices?

    Acura Pharmaceuticals has offices in Palatine and Culver.

  • How many offices does Acura Pharmaceuticals have?

    Acura Pharmaceuticals has 2 offices.